Copyright Reports & Markets. All rights reserved.

Global Fragile X Syndrome Market Professional Survey Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Industry Overview of Fragile X Syndrome

      • 1.1 Definition of Fragile X Syndrome
      • 1.2 Fragile X Syndrome Segment by Type
        • 1.2.1 Global Fragile X Syndrome Production Growth Rate Comparison by Types (2014-2025)
        • 1.2.2 ACT-01
        • 1.2.3 AMO-01
        • 1.2.4 ANAVEX-273
        • 1.2.5 AUT-00206
        • 1.2.6 Bryostatin-1
        • 1.2.7 Cannabidiol
        • 1.2.8 Others
      • 1.3 Fragile X Syndrome Segment by Applications
        • 1.3.1 Global Fragile X Syndrome Consumption Comparison by Applications (2014-2025)
        • 1.3.2 Clinic
        • 1.3.3 Hopital
        • 1.3.4 Research Center
      • 1.4 Global Fragile X Syndrome Overall Market
        • 1.4.1 Global Fragile X Syndrome Revenue (2014-2025)
        • 1.4.2 Global Fragile X Syndrome Production (2014-2025)
        • 1.4.3 North America Fragile X Syndrome Status and Prospect (2014-2025)
        • 1.4.4 Europe Fragile X Syndrome Status and Prospect (2014-2025)
        • 1.4.5 China Fragile X Syndrome Status and Prospect (2014-2025)
        • 1.4.6 Japan Fragile X Syndrome Status and Prospect (2014-2025)
        • 1.4.7 Southeast Asia Fragile X Syndrome Status and Prospect (2014-2025)
        • 1.4.8 India Fragile X Syndrome Status and Prospect (2014-2025)

      2 Manufacturing Cost Structure Analysis

      • 2.1 Raw Material and Suppliers
      • 2.2 Manufacturing Cost Structure Analysis of Fragile X Syndrome
      • 2.3 Manufacturing Process Analysis of Fragile X Syndrome
      • 2.4 Industry Chain Structure of Fragile X Syndrome

      3 Development and Manufacturing Plants Analysis of Fragile X Syndrome

      • 3.1 Capacity and Commercial Production Date
      • 3.2 Global Fragile X Syndrome Manufacturing Plants Distribution
      • 3.3 Major Manufacturers Technology Source and Market Position of Fragile X Syndrome
      • 3.4 Recent Development and Expansion Plans

      4 Key Figures of Major Manufacturers

      • 4.1 Fragile X Syndrome Production and Capacity Analysis
      • 4.2 Fragile X Syndrome Revenue Analysis
      • 4.3 Fragile X Syndrome Price Analysis
      • 4.4 Market Concentration Degree

      5 Fragile X Syndrome Regional Market Analysis

      • 5.1 Fragile X Syndrome Production by Regions
        • 5.1.1 Global Fragile X Syndrome Production by Regions
        • 5.1.2 Global Fragile X Syndrome Revenue by Regions
      • 5.2 Fragile X Syndrome Consumption by Regions
      • 5.3 North America Fragile X Syndrome Market Analysis
        • 5.3.1 North America Fragile X Syndrome Production
        • 5.3.2 North America Fragile X Syndrome Revenue
        • 5.3.3 Key Manufacturers in North America
        • 5.3.4 North America Fragile X Syndrome Import and Export
      • 5.4 Europe Fragile X Syndrome Market Analysis
        • 5.4.1 Europe Fragile X Syndrome Production
        • 5.4.2 Europe Fragile X Syndrome Revenue
        • 5.4.3 Key Manufacturers in Europe
        • 5.4.4 Europe Fragile X Syndrome Import and Export
      • 5.5 China Fragile X Syndrome Market Analysis
        • 5.5.1 China Fragile X Syndrome Production
        • 5.5.2 China Fragile X Syndrome Revenue
        • 5.5.3 Key Manufacturers in China
        • 5.5.4 China Fragile X Syndrome Import and Export
      • 5.6 Japan Fragile X Syndrome Market Analysis
        • 5.6.1 Japan Fragile X Syndrome Production
        • 5.6.2 Japan Fragile X Syndrome Revenue
        • 5.6.3 Key Manufacturers in Japan
        • 5.6.4 Japan Fragile X Syndrome Import and Export
      • 5.7 Southeast Asia Fragile X Syndrome Market Analysis
        • 5.7.1 Southeast Asia Fragile X Syndrome Production
        • 5.7.2 Southeast Asia Fragile X Syndrome Revenue
        • 5.7.3 Key Manufacturers in Southeast Asia
        • 5.7.4 Southeast Asia Fragile X Syndrome Import and Export
      • 5.8 India Fragile X Syndrome Market Analysis
        • 5.8.1 India Fragile X Syndrome Production
        • 5.8.2 India Fragile X Syndrome Revenue
        • 5.8.3 Key Manufacturers in India
        • 5.8.4 India Fragile X Syndrome Import and Export

      6 Fragile X Syndrome Segment Market Analysis (by Type)

      • 6.1 Global Fragile X Syndrome Production by Type
      • 6.2 Global Fragile X Syndrome Revenue by Type
      • 6.3 Fragile X Syndrome Price by Type

      7 Fragile X Syndrome Segment Market Analysis (by Application)

      • 7.1 Global Fragile X Syndrome Consumption by Application
      • 7.2 Global Fragile X Syndrome Consumption Market Share by Application (2014-2019)

      8 Fragile X Syndrome Major Manufacturers Analysis

      • 8.1 Aelis Farma SAS
        • 8.1.1 Aelis Farma SAS Fragile X Syndrome Production Sites and Area Served
        • 8.1.2 Aelis Farma SAS Product Introduction, Application and Specification
        • 8.1.3 Aelis Farma SAS Fragile X Syndrome Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.1.4 Main Business and Markets Served
      • 8.2 Alcobra Ltd
        • 8.2.1 Alcobra Ltd Fragile X Syndrome Production Sites and Area Served
        • 8.2.2 Alcobra Ltd Product Introduction, Application and Specification
        • 8.2.3 Alcobra Ltd Fragile X Syndrome Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.2.4 Main Business and Markets Served
      • 8.3 AMO Pharma Limited
        • 8.3.1 AMO Pharma Limited Fragile X Syndrome Production Sites and Area Served
        • 8.3.2 AMO Pharma Limited Product Introduction, Application and Specification
        • 8.3.3 AMO Pharma Limited Fragile X Syndrome Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.3.4 Main Business and Markets Served
      • 8.4 Confluence Pharmaceuticals LLC
        • 8.4.1 Confluence Pharmaceuticals LLC Fragile X Syndrome Production Sites and Area Served
        • 8.4.2 Confluence Pharmaceuticals LLC Product Introduction, Application and Specification
        • 8.4.3 Confluence Pharmaceuticals LLC Fragile X Syndrome Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.4.4 Main Business and Markets Served
      • 8.5 Eli Lilly and Company
        • 8.5.1 Eli Lilly and Company Fragile X Syndrome Production Sites and Area Served
        • 8.5.2 Eli Lilly and Company Product Introduction, Application and Specification
        • 8.5.3 Eli Lilly and Company Fragile X Syndrome Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.5.4 Main Business and Markets Served
      • 8.6 F. Hoffmann-La Roche Ltd.
        • 8.6.1 F. Hoffmann-La Roche Ltd. Fragile X Syndrome Production Sites and Area Served
        • 8.6.2 F. Hoffmann-La Roche Ltd. Product Introduction, Application and Specification
        • 8.6.3 F. Hoffmann-La Roche Ltd. Fragile X Syndrome Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.6.4 Main Business and Markets Served
      • 8.7 Marinus Pharmaceuticals, Inc.
        • 8.7.1 Marinus Pharmaceuticals, Inc. Fragile X Syndrome Production Sites and Area Served
        • 8.7.2 Marinus Pharmaceuticals, Inc. Product Introduction, Application and Specification
        • 8.7.3 Marinus Pharmaceuticals, Inc. Fragile X Syndrome Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.7.4 Main Business and Markets Served
      • 8.8 MI.TO. Technology S.r.L.
        • 8.8.1 MI.TO. Technology S.r.L. Fragile X Syndrome Production Sites and Area Served
        • 8.8.2 MI.TO. Technology S.r.L. Product Introduction, Application and Specification
        • 8.8.3 MI.TO. Technology S.r.L. Fragile X Syndrome Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.8.4 Main Business and Markets Served
      • 8.9 Neuren Pharmaceuticals Limited
        • 8.9.1 Neuren Pharmaceuticals Limited Fragile X Syndrome Production Sites and Area Served
        • 8.9.2 Neuren Pharmaceuticals Limited Product Introduction, Application and Specification
        • 8.9.3 Neuren Pharmaceuticals Limited Fragile X Syndrome Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.9.4 Main Business and Markets Served
      • 8.10 Ovid Therapeutics Inc.
        • 8.10.1 Ovid Therapeutics Inc. Fragile X Syndrome Production Sites and Area Served
        • 8.10.2 Ovid Therapeutics Inc. Product Introduction, Application and Specification
        • 8.10.3 Ovid Therapeutics Inc. Fragile X Syndrome Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.10.4 Main Business and Markets Served
      • 8.11 Sage Therapeutics, Inc.
      • 8.12 Zynerba Pharmaceuticals, Inc.

      9 Development Trend of Analysis of Fragile X Syndrome Market

      • 9.1 Global Fragile X Syndrome Market Trend Analysis
        • 9.1.1 Global Fragile X Syndrome Market Size (Volume and Value) Forecast 2019-2025
      • 9.2 Fragile X Syndrome Regional Market Trend
        • 9.2.1 North America Fragile X Syndrome Forecast 2019-2025
        • 9.2.2 Europe Fragile X Syndrome Forecast 2019-2025
        • 9.2.3 China Fragile X Syndrome Forecast 2019-2025
        • 9.2.4 Japan Fragile X Syndrome Forecast 2019-2025
        • 9.2.5 Southeast Asia Fragile X Syndrome Forecast 2019-2025
        • 9.2.6 India Fragile X Syndrome Forecast 2019-2025
      • 9.3 Fragile X Syndrome Market Trend (Product Type)
      • 9.4 Fragile X Syndrome Market Trend (Application)
      • 10.1 Marketing Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.3 Fragile X Syndrome Customers

      11 Market Dynamics

      • 11.1 Market Trends
      • 11.2 Opportunities
      • 11.3 Market Drivers
      • 11.4 Challenges
      • 11.5 Influence Factors

      12 Conclusion

        13 Appendix

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        The global Fragile X Syndrome market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
        This report focuses on Fragile X Syndrome volume and value at global level, regional level and company level. From a global perspective, this report represents overall Fragile X Syndrome market size by analyzing historical data and future prospect.
        Regionally, this report categorizes the production, apparent consumption, export and import of Fragile X Syndrome in North America, Europe, China, Japan, Southeast Asia and India.
        For each manufacturer covered, this report analyzes their Fragile X Syndrome manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

        The following manufacturers are covered:
        Aelis Farma SAS
        Alcobra Ltd
        AMO Pharma Limited
        Confluence Pharmaceuticals LLC
        Eli Lilly and Company
        F. Hoffmann-La Roche Ltd.
        Marinus Pharmaceuticals, Inc.
        MI.TO. Technology S.r.L.
        Neuren Pharmaceuticals Limited
        Ovid Therapeutics Inc.
        Sage Therapeutics, Inc.
        Zynerba Pharmaceuticals, Inc.

        Segment by Regions
        North America
        Europe
        China
        Japan
        Southeast Asia
        India

        Segment by Type
        ACT-01
        AMO-01
        ANAVEX-273
        AUT-00206
        Bryostatin-1
        Cannabidiol
        Others

        Segment by Application
        Clinic
        Hopital
        Research Center

        Buy now